Influence of antiphospholipid antibody levels and type on thrombotic manifestations: Results from the Serbian National Cohort Study

Lupus

Volumn 21, Issue 3, 2012, Pages 338-345

  Stojanovich, L ^a   Markovic, O ^a   Marisavljevic, D ^a,b   Elezovic, I ^b,c   Ilijevski, N ^b,d   Stanisavljevic, N ^a  

^a University Medical Center   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d Institute of Cardiovascular Disease Dedinje   (Serbia)

Author keywords

antiphospholipid antibodies; antiphospholipid syndrome; Hughes syndrome; systemic lupus erythematosus; thrombosis

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SERBIA; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ADULT; AGE FACTORS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COHORT STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SERBIA; THROMBOSIS; VENOUS THROMBOSIS;

EID: 84856715204     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311422710     Document Type: Article

References (47)

1. Asherson RA, Cervera R, Piette JC, Shoenfeld Y The antiphospholipid syndrome. Asherson RA Cervera R Piette JC Shoenfeld Y, ed. Boca Raton, FL: CRC Press ; 1996: 3-12.
2. Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the standardisation of the antiphospholipid antibodies. Lupus. 2009 ; 18: 913-919
3. Nair S, Khamashta MA, Hughes GRV. Syndrome X and Hughes syndrome. Lupus. 2002 ; 11: 332-339
4. Khamashta MA Hughes Syndrome, Antiphospholipid Syndrome. 2 nd ed. London: Springer; 2006. Khamashta MA, ed. London: Springer ; 2006 :
5. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010 ; 376: 1498-1509
6. Asherson RA, Cervera R, Klumb E, et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum. 2008 ; 38: 124-131
7. Stojanovich L, Marisavljevic D, Rovensky J, Djokovich A, Kozakova D, Milinic N. Clinical and laboratory features of the catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009 ; 36: 74-79
8. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995 ; 91: 23-27
9. Marai I, Levi Y, Godard G, Shoenfeld Y. Following 90 patients with antiphospholipid syndrome with antibody levels and associations with clinical manifestations: symptoms of the disease, a new antibody and associations with clinical manifestations in the Israeli population. Harefuah. 2001 ; 140: 495-500
10. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003 ; 1: 1827-1832 (Pubitemid 36237580)
11. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome?. J Autoimmun. 2000 ; 15: 163-172
12. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005 ; 93: 1147-1152 (Pubitemid 40823521)
13. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996 ; 100: 530-533
14. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007 ; 16: 39-45 (Pubitemid 46174314)
15. Cervera R, Piette JC, Font J, et al. Clinical and immunological manifestation and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002 ; 46: 1019-1027 (Pubitemid 34303815)
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277 (Pubitemid 13221242)
17. Bombardieri C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
18. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
19. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995 ; 74: 1185-1190
20. Amigo MC, Khamashta MA, Hughes GR. Antiphospholipid syndrome in SLE. Baillieres Clin Rheumatol. 1998 ; 12: 477-493 (Pubitemid 28488244)
21. Camps G, Fernández N, Díaz C, Haro L, Barón R, de Ramón G. Clinical and immunological features in 112 patients with antiphospholipid syndrome. Med Clin (Barc). 2004 ; 123: 466-470 (Pubitemid 39506111)
22. Hughes GRV. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes) syndrome. Post Med J. 2003 ; 79: 81-83 (Pubitemid 36286620)
23. Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev. 2006 ; 5: 344-348 (Pubitemid 43868201)
24. Suvajac G, Stojanovich L, Milenkovich S. Ocular manifestations of antiphospholipid syndrome. Autoimmun Rev. 2006 ; 6: 409-414
25. Meroni PL, Moia M, Derksen RH, et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus. 2003 ; 12: 504-507 (Pubitemid 36890140)
26. Williams FM, Chinn S, Hughes GR, Leach RM. Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome. Ann Rheum Dis. 2002 ; 61: 414-421 (Pubitemid 34496820)
27. Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009 ; 36: 1195-1199
28. Wahl DG, Guillemin F, de Maistre E, Regnault V, Perret-Guillaume C, Lecompte T. Meta-analysis of the risk venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998 ; 7: 15-22 (Pubitemid 28052657)
29. De Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Throm Haemost. 2005 ; 160: 2042-2048
30. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996 ; 76: 916-924
31. Autoantibodies. Peter JB Shoenfeld Y, ed. Amsterdam, The Netherlands: Elsevier ; 1996: 1-880.
32. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009 ; 8: 998-1005
33. Ruffatti A, Del Ross TD, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009 ; 68: 397-399
34. Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome. A 5-year prospective study. Stroke. 2005 ; 36: 1490-1494 (Pubitemid 40967518)
35. Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high levels anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost. 2003 ; 90: 108-115 (Pubitemid 36873866)
36. Shovman O, Gilburd B, Barzilai O, Langevitz P, Shoenfeld Y. Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome. Clin Rev Allergy Immunol. 2007 ; 32: 145-152 (Pubitemid 47571437)
37. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestation of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with beta2GPI than with other antiphospholipid antibodies. J Reumatol. 1995 ; 22: 1899-1906
38. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical associations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol. 2003 ; 23: 377-383 (Pubitemid 37083192)
39. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005 ; 3: 1231-1238 (Pubitemid 41725247)
40. Tarr T, Lakos G, Bhattoa HP, et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol. 2007 ; 32: 131-137 (Pubitemid 47571435)
41. Meroni PL, Shoenfeld Y. Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmune Rev. 2008 ; 7: 585-587
42. Cucnik S, Kveder T, Križaj I, Rozman B, Bozic B. High avidity anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis. 2004 ; 63: 1478-1482 (Pubitemid 39433954)
43. Shoenfeld Y, Meroni PL, Cervera R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis. 2008 ; 67: 438-442 (Pubitemid 351498420)
44. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet. 1993 ; 342: 341-344 (Pubitemid 23227565)
45. Bertolaccini ML, Khamashta MA, Hughes GR. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2005 ; 1: 40-46
46. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford). 2003 ; 42: 200-213 (Pubitemid 36305604)
47. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 ; 69: 20-28